Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 7/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100453 | 0.80 | METAP1 (0.47) | METAP1CYP17A1ATRLCKKDM4E | |
| SCHEMBL26115808 | 0.79 | ATR (0.41) | METAP1CYP17A1ATRCA1CA2 | |
| SCHEMBL31278313 | 0.79 | ATR (0.41) | METAP1CYP17A1ATRCA1CA2 | |
| SCHEMBL1697865 | 0.72 | BRAF (0.42) | METAP1CA1MAP4K4POLBCA12 | |
| SCHEMBL31418587 | 0.71 | LCK (0.45) | METAP1CA1CA2LCK | |
| SCHEMBL15264820 | 0.71 | ATR (0.48) | METAP1CYP17A1ATRCA1CA2 | |
| SCHEMBL26542469 | 0.71 | ATR (0.35) | METAP1CYP17A1ATRCA1CA2 | |
| SCHEMBL14507524 | 0.70 | CA1 (0.41) | METAP1CYP17A1ATRCA1CA2 | |
| SCHEMBL8233779 | 0.70 | LCK (0.41) | CYP17A1CA1CA2LCKCA12 | |
| SCHEMBL289636 | 0.70 | LCK (0.41) | METAP1CYP17A1ATRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576566-B1 | THIENO(2,3B)PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | MERCK SHARP & DOHME (NL) | 2015-10-28 | — | — | EP | disclosed |
| EP-2576566-B1 | THIENO(2,3B)PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | MERCK SHARP & DOHME (NL) | 2015-10-28 | — | — | EP | disclosed |
| US-8669256-B2 | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity | MERCK SHARP & DOHME B.V. (NL) | 2014-03-11 | — | — | US | disclosed |
| US-8669256-B2 | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity | MERCK SHARP & DOHME B.V. (NL) | 2014-03-11 | — | — | US | disclosed |
| EP-2576566-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | MSD Oss B.V. (NL) | 2013-04-10 | — | — | EP | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| WO-2011147764-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | N.V. ORGANON (NL) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147764-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | N.V. ORGANON (NL) | 2011-12-01 | — | — | WO | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | METAP1 2625/4885CYP17A1 4639/4885ATR 188/4885 |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | METAP1 4011/4885CYP17A1 2927/4885ATR 611/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | METAP1 1935/4885CYP17A1 4110/4885ATR 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.